Novartis Pharmaceuticals [clinicaltrials_resource:d28184c892b63a38ec1af3826692b814]
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria [clinicaltrials:NCT00097955]Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes [clinicaltrials:NCT00099853]Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes [clinicaltrials:NCT00099892]A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes [clinicaltrials:NCT00099905]Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes [clinicaltrials:NCT00099918]Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes [clinicaltrials:NCT00099944]Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes [clinicaltrials:NCT00101803]Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease [clinicaltrials:NCT00104442]Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes [clinicaltrials:NCT00106340]Terbinafine Compared to Griseofulvin in Children With Tinea Capitis [clinicaltrials:NCT00117754]Terbinafine Compared to Griseofulvin in Children With Tinea Capitis [clinicaltrials:NCT00117767]Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes [clinicaltrials:NCT00120536]Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension [clinicaltrials:NCT00136851]Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes [clinicaltrials:NCT00138515]Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes [clinicaltrials:NCT00138541]Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes [clinicaltrials:NCT00138554]Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes [clinicaltrials:NCT00138580]Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes [clinicaltrials:NCT00138606]Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes [clinicaltrials:NCT00138619]Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension [clinicaltrials:NCT00139555]To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure. [clinicaltrials:NCT00170924]Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension [clinicaltrials:NCT00171535]Atrial Fibrillation Feasibility Certoparin Trial - AFFECT [clinicaltrials:NCT00171769]A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients. [clinicaltrials:NCT00219089]A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg [clinicaltrials:NCT00219115]A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure. [clinicaltrials:NCT00219128]clinicaltrials:NCT00219141Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure [clinicaltrials:NCT00219180]A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients [clinicaltrials:NCT00219193]Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes [clinicaltrials:NCT00237237]Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance [clinicaltrials:NCT00237250]An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States [clinicaltrials:NCT00237263]A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension [clinicaltrials:NCT00241007]A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan. [clinicaltrials:NCT00250562]A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure [clinicaltrials:NCT00260923]Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension [clinicaltrials:NCT00273299]Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension [clinicaltrials:NCT00280540]A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure [clinicaltrials:NCT00294086]Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes [clinicaltrials:NCT00351884]clinicaltrials:NCT00368277
location [clinicaltrials_vocabulary:location]
Novartis Pharmaceuticals [clinicaltrials_resource:d28184c892b63a38ec1af3826692b814]
Bio2RDF identifier
d28184c892b63a38ec1af3826692b814
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d28184c892b63a38ec1af3826692b814
address [clinicaltrials_vocabulary:address]
identifier
clinicaltrials_resource:d28184c892b63a38ec1af3826692b814
title
Novartis Pharmaceuticals
@en
type
label
Novartis Pharmaceuticals [clinicaltrials_resource:d28184c892b63a38ec1af3826692b814]
@en